CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that David Spellman, Chief Financial Officer, will present a company overview at
the H.C. Wainwright Global Life Sciences Conference in London, UK on Monday, April 8, 2019 at 11:10 a.m. BST.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the
presentation.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and
its modular Synthemer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver
meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients
with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners
are using Mersana’s platform to advance their ADC pipelines.
Contact:
Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com
